Cagrilintide C194H312N54O59S2 CID 171397054 PubChem Presented at the ADA 85th Scientific Sessions: In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Cagrilintide: What It Is and How It's Being Studied for Weight Loss New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) CagrilintideSemaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)